

# MarÃ-a JesÃºs PÃ©rez-ElÃ-as

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/335154/publications.pdf>

Version: 2024-02-01

50  
papers

795  
citations

687363

13  
h-index

552781

26  
g-index

55  
all docs

55  
docs citations

55  
times ranked

1185  
citing authors

#	ARTICLE	IF	CITATIONS
1	Antiretroviral treatment adherence and mental disorders: observational case-control study in people living with HIV in Spain. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2022, 34, 1064-1072.	1.2	1
2	Beneficio clnico y econmico de 32 aos de tratamiento antirretroviral de personas que viven con VIH en Espaa: ha sido una intervencin eficiente?. <i>Enfermedades Infecciosas Y Microbiologa Clnica</i> , 2022, 40, 550-556.	0.5	0
3	Similar humoral immune responses against the SARS-CoV-2 spike protein in HIV and non-HIV individuals after COVID-19. <i>Journal of Infection</i> , 2022, 84, 418-467.	3.3	7
4	Severe Acute Respiratory Syndrome Coronavirus 2 Spreads to Lymph Nodes and Strongly Expands CD4+ Effector Memory RA Cells in a Patient With Mild Coronavirus Disease 2019. <i>Clinical Infectious Diseases</i> , 2021, 73, e3970-e3973.	5.8	2
5	Hepatitis C and HIV combined screening in primary care: A cluster randomized trial. <i>Journal of Viral Hepatitis</i> , 2021, 28, 345-352.	2.0	7
6	HIV testing in Spain: Are we doing our job?. <i>Enfermedades Infecciosas Y Microbiologa Clnica</i> , 2021, 39, 1-2.	0.5	1
7	Self-rated health among people living with HIV in Spain in 2019: a cross-sectional study. <i>BMC Infectious Diseases</i> , 2021, 21, 129.	2.9	2
8	Dynamics of creatinine estimated glomerular filtration rate using one or more antiretrovirals that inhibit creatinine tubular secretion. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 1046-1050.	3.0	2
9	2021 update to HIV-TRePS: a highly flexible and accurate system for the prediction of treatment response from incomplete baseline information in different healthcare settings. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 1898-1906.	3.0	1
10	Weight changes after antiretroviral therapy initiation in CoRIS (Spain): a prospective multicentre cohort study. <i>Journal of the International AIDS Society</i> , 2021, 24, e25732.	3.0	14
11	Personality and adherence to antiretroviral therapy in HIV-infected adult patients. <i>Journal of Psychosomatic Research</i> , 2021, 144, 110413.	2.6	3
12	Prevalence and factors associated with SARS-CoV-2 seropositivity in the Spanish HIV Research Network Cohort. <i>Clinical Microbiology and Infection</i> , 2021, 27, 1678-1684.	6.0	34
13	Clinical and economic benefit of 32 years of antiretroviral treatment for people living with HIV in Spain: Has it been an efficient intervention?. <i>Enfermedades Infecciosas Y Microbiologia Clinica (English)</i> Tj ETQq1 10.784314rgBT/O		
14	Differences in epidemiology and mortality between men and women with HIV infection in the CoRIS cohort from 2004 to 2014. <i>Enfermedades Infecciosas Y Microbiologia Clinica (English Ed)</i> , 2021, 39, 372-382.	0.3	1
15	Diferencias epidemiolgicas y de mortalidad entre hombres y mujeres con infeccin por VIH en la cohorte CoRIS entre los aos 2004 y 2014. <i>Enfermedades Infecciosas Y Microbiologa Clnica</i> , 2021, 39, 372-382.	0.5	5
16	Implementation of a lung cancer screening initiative in HIV-infected subjects. <i>PLoS ONE</i> , 2021, 16, e0260069.	2.5	4
17	Factors associated with the number of drugs in darunavir/cobicistat regimens. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 208-214.	3.0	4
18	Effectiveness of the combination elvitegravir/cobicistat/tenofovir/emtricitabine (EVG/COB/TFV/FTC) plus darunavir among treatment-experienced patients in clinical practice: a multicentre cohort study. <i>AIDS Research and Therapy</i> , 2020, 17, 45.	1.7	1

#	ARTICLE	IF	CITATIONS
19	Psychological distress in women and men living with HIV in Spain: a cross-sectional telephone survey. <i>Evidence-Based Mental Health</i> , 2020, 23, 91-99.	4.5	4
20	Primary resistance to integrase strand transfer inhibitors in Spain using ultrasensitive HIV-1 genotyping. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 3517-3524.	3.0	6
21	Risk, Diagnostic and Predictor Factors for Classical Hodgkin Lymphoma in HIV-1-Infected Individuals: Role of Plasma Exosome-Derived miR-20a and miR-21. <i>Journal of Clinical Medicine</i> , 2020, 9, 760.	2.4	13
22	Increased HIV infection in patients with stroke in Spain. A 16-year population-based study. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2020, 38, 219-225.	0.5	8
23	Prevalencia de la infección por el VHC en un Área sanitaria de Madrid: el primer paso para la microeliminación. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2020, 38, 317-322.	0.5	1
24	Impact of a structured HIV testing program in a hospital emergency department and a primary care center. <i>PLoS ONE</i> , 2019, 14, e0220375.	2.5	18
25	Outcome of an HIV education program for primary care providers: Screening and late diagnosis rates. <i>PLoS ONE</i> , 2019, 14, e0218380.	2.5	12
26	Frailty phenotype: a clinical marker of age acceleration in the older HIV-infected population. <i>Epigenomics</i> , 2019, 11, 501-509.	2.1	21
27	Outcomes by sex following treatment initiation with darunavir/cobicistat in a large Spanish cohort of the CODAR study (GeSIDA 9316). <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 3044-3048.	3.0	2
28	Surveillance of transmitted drug resistance to integrase inhibitors in Spain: implications for clinical practice. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 1693-1700.	3.0	19
29	High CD8 T cell percentage and HCV replication control are common features in HIV-1 controllers and HTLV-2-co-infected patients with a history of injection drug use. <i>Virus Research</i> , 2019, 264, 40-44.	2.2	6
30	Drug-related and psychopathological symptoms in HIV-positive men who have sex with men who inject drugs during sex (slamsex): Data from the U-SEX GESIDA 9416 Study. <i>PLoS ONE</i> , 2019, 14, e0220272.	2.5	31
31	Combined Effect of Sex and Age in Response to Antiretroviral Therapy in HIV-Infected Patients. <i>Antiviral Therapy</i> , 2017, 22, 21-29.	1.0	4
32	Frailty and physical function in older HIV-infected adults. <i>Age and Ageing</i> , 2017, 46, 522-526.	1.6	47
33	Development and Validation of an HIV Risk Exposure and Indicator Conditions Questionnaire to Support Targeted HIV Screening. <i>Medicine (United States)</i> , 2016, 95, e2612.	1.0	15
34	Use of maraviroc in patients with undetectable viral load: efficacy, tolerance and predictors of viral response in MARAVIROC-cohort study. <i>Journal of the International AIDS Society</i> , 2014, 17, 19800.	3.0	1
35	Incremental cost per newly diagnosed HIV infection (NDHI): routine (RTS), targeted (TTS), and current clinical practice testing strategies (CPTS). <i>Journal of the International AIDS Society</i> , 2014, 17, 19606.	3.0	4
36	Increased Risk of Serious Non-AIDS-Related Events in HIV-Infected Subjects on Antiretroviral Therapy Associated with a Low CD4/CD8 Ratio. <i>PLoS ONE</i> , 2014, 9, e85798.	2.5	175

#	ARTICLE	IF	CITATIONS
37	Virological response to short-course maraviroc monotherapy does not predict viral tropism in HIV-1-infected treatment-naïve patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 1916-1919.	3.0	6
38	Comparison of routine versus targeted HIV testing strategies: coverage and estimated missed infections in emergency room and primary care centre. <i>Journal of the International AIDS Society</i> , 2014, 17, 19671.	3.0	5
39	Genotypic tropism testing in proviral DNA to guide maraviroc initiation in aviremic subjects: 48-week analysis of the PROTEST study. <i>Journal of the International AIDS Society</i> , 2014, 17, 19520.	3.0	2
40	Transmission of HIV drug resistance and non-B subtype distribution in the Spanish cohort of antiretroviral treatment naïve HIV-infected individuals (CoRIS). <i>Antiviral Research</i> , 2011, 91, 150-153.	4.1	37
41	Pharmacokinetics of Fosamprenavir plus Ritonavir in Human Immunodeficiency Virus Type 1-Infected Adult Subjects with Hepatic Impairment. <i>Antimicrobial Agents and Chemotherapy</i> , 2009, 53, 5185-5196.	3.2	15
42	Short-Term Effect of Ritonavir-Boosted Atazanavir in Hepatitis B and/or C Co-infected, Treatment-Experienced HIV Patients. <i>HIV Clinical Trials</i> , 2009, 10, 269-275.	2.0	10
43	Risk factors for loss of virological suppression in patients receiving lopinavir/ritonavir monotherapy for maintenance of HIV suppression. <i>Antiviral Therapy</i> , 2009, 14, 195-201.	1.0	51
44	Atazanavir: simplicity and convenience in different scenarios. <i>Expert Opinion on Pharmacotherapy</i> , 2007, 8, 689-700.	1.8	9
45	High virological failure rate in HIV patients after switching to a regimen with two nucleoside reverse transcriptase inhibitors plus tenofovir. <i>Aids</i> , 2005, 19, 695-698.	2.2	22
46	Higher Virological Effectiveness of NNRTI-Based Antiretroviral Regimens Containing Nevirapine or Efavirenz Compared to a Triple NRTI Regimen As Initial Therapy in HIV-1-Infected Adults. <i>HIV Clinical Trials</i> , 2005, 6, 312-319.	2.0	11
47	High Rate of Didanosine-Related Mitochondrial Toxicity in HIV/HCV-Coinfected Patients Receiving Ribavirin. <i>Antiviral Therapy</i> , 2004, 9, 133-138.	1.0	88
48	Differences in Durability of Treatment with Initial PI-Based Regimens. <i>HIV Clinical Trials</i> , 2003, 4, 391-399.	2.0	5
49	Patients Failing Saquinavir Therapy Require an Early Change to Indinavir before HIV-1 Viral Load Reaches High Levels. <i>Antiviral Therapy</i> , 1999, 4, 117-121.	1.0	0
50	Clinical features of adrenal insufficiency in patients with acquired immunodeficiency syndrome. <i>Clinical Endocrinology</i> , 1996, 45, 97-101.	2.4	50